Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1,001 - 10,000 - Monthly Reach
Unique listeners across all episodes (30 days)
5,001 - 25,000 - Active Followers
Loyal subscribers who consistently listen
5,001 - 15,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Some clinical trial news of the day (March 27, 2026 - **updated March 29th**)
Mar 29, 2026
Unknown duration
Reddit Q&A 3/17/2026 pt 1 (no song); Peter sits down with Brad our Angry Dad
Mar 27, 2026
Unknown duration
Our takes on recent (~Jan 2026) FSHD clinical trial updates
Jan 15, 2026
Unknown duration
All-in-one version of our evaluation of EPI-321 data and trial
Sep 14, 2025
Unknown duration
Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data
Sep 6, 2025
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 3/29/26 | Some clinical trial news of the day (March 27, 2026 - **updated March 29th**) | "Blue Horseshoe loves Anacott Steel." Today we cover recent clinical trial news in the FSHD space and delve a bit deeper into some topics from part 1 of our Reddit Q&A. **Updated version**The lowlight was Roche canceling their trial. The highlight was Sarepta's announcement of preliminary clinical data. Getting siRNAs, ASOs, and viruses into liver is easy because liver is filled with leaky capillaries, however, muscle is poorly vascularized and blood vessels have tight junctions so targeting cell receptors for enhanced transcytosis greatly enhances skeletal muscle delivery. Sarepta's targeting of the alpha v beta 6 integrin is a great advance in delivery of siRNA against DUX4 and, as predicted, shows the best DUX4 knockdown we have seen so far. | — | ||||||
| 3/27/26 | Reddit Q&A 3/17/2026 pt 1 (no song); Peter sits down with Brad our Angry Dad | "I am the eyes and ears of this institution, my friends." You asked, we (try to) answer your questions. Part 1 of 2. There is no song in this version due to copyright issues causing it to be removed for some of our international listeners, otherwise, same as the original version. | — | ||||||
| 1/15/26 | Our takes on recent (~Jan 2026) FSHD clinical trial updates | "So, Mr Tipton, how could it take you five minutes to cook your grits when it takes the entire grit-eating world twenty minutes?" We discuss the initial Epicrispr Biotech press release pertaining to their EPI-321 phase 1/2 clinical trial and the big picture science behind the RESTEM phase 1/2 clinical trial in progress and the Scholar Rock upcoming phase 2 clinical trial. | — | ||||||
| 9/14/25 | All-in-one version of our evaluation of EPI-321 data and trial | "There's another old saying, Senator: Don't piss down my back and tell me it's raining." We know a lot of you don't have the time or interest in all the details so we packaged up the highlights of the gene therapy series, with some new information and evaluation, too, into one shorter (but not short enough, we know) episode. | — | ||||||
| 9/6/25 | Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data | "But did you bleed him? - Aesculapius says that bleeding is not a cure. It is only a way of proving that you are a physician at the expense of your patient." Finally, we discuss the EPI-321 epigenetic editing phase I/II clinical trial design and its potential for answering key questions necessary for going to phase III and for providing benefit to participants and patients. | — | ||||||
| 9/6/25 | Our scientific evaluation of and opinions on the EPI-321 publicly available preclinical data | "Good morning, and in case I don't see ya, good afternoon, good evening, and good night!" We take our time to evaluate publicly available preclinical data for EPI-321 used to support the Epicrispr Biotechnology first-in-human gene therapy clinical trial for FSHD. We discuss the data in the context of what is known from other neuromuscular disease gene therapy trials and integrate their own data in respect to what metrics are likely needed to be met for have any chance at providing benefit to patients. | — | ||||||
| 9/6/25 | Prequel for the Epicrispr Bio data and clinical trial discussion | "In the history of science, innovative concepts occasionally arise from sudden left-field inspiration." Here we make sure everyone is up to speed on the types of CRISPR inhibition for FSHD and FSHD epigenetics s that we are all ready to evaluate the preclinical data supporting the Epicrispr Biotechnology EPI321 clinical trial. | — | ||||||
| 8/17/25 |  The nuts and bolts of gene therapy for FSHD (Part 2 of 2) | "...and by the time they figure out what went wrong, we'll be sitting on a beach, earning twenty percent." This is part 2 of our podcast series covering the important factors in successful gene therapy and introduces the knowledge gained from other neuromuscular diseases and how it can be applied to positively impact gene therapy in FSHD. In part 2, we focus on viral dosing and how it affects therapeutic biodistribution and expression. In addition, we reveal what is known about variable durability of transgene expression and what to look for to predict a durable, or non-durable, therapeutic. Check out the MyFSHD Youtube for the music, as well. | — | ||||||
| 8/15/25 |  The nuts and bolts of gene therapy for FSHD (Part 1 of 2) | "My friends are toys. I make them. It's a hobby. I'm a genetic designer." This is a two part podcast covering the important factors is successful gene therapy and introduces the knowledge gained from other neuromuscular diseases and how it can be used to positively impact gene therapy in FSHD. In part 1, we focus on AAV serotypes, transgene constructs, immune responses, and delivery. We look into DMD gene therapy and how that can impact the current FSHD gene therapy programs. Check us out on the MyFSHD Youtube channel as well. | — | ||||||
| 7/30/25 |  Part 2 of our discussion with our teen FSHD advocates | "You were seeking some information of some kind?" Continuing our discussion with our young FSHD advocates, asking and answering some questions. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/28/25 |  Teens promoting their "Cure FSHD for All" initiative, podcast part 1 | "And that would tell you what is obvious right now? That avoiding apple skins and pizza has no effect on this brutal disease?" Today we discuss the Cure FSHD for All (go to: www.curefshdforall.com) initiative for inclusion of FSHDers under 18 and those with limited mobility into clinical trials and for access to developing therapies. | — | ||||||
| 6/24/25 |  MyFSHD is worldwide on FSHD Day | "You're gonna need a bigger boat." MyFSHD is our summer blockbuster passion project. We discuss how to get it done, whatever your "it" is, in the FSHD space, as well as our trip to Shanghai and Hanoi to continue our efforts to help FSHDers around the world. | — | ||||||
| 6/11/25 | Our take on Avidity's FORTITUDE phase 1/2 trial data | "I'll have what she's having." We'll take you through and discuss the recent release of Avidity Biosciences topline results from the phase 1/2 FORTITUDE trial and the preliminary data from the biomarker cohort extension. | — | ||||||
| 4/12/25 |  FaceToned® Exercises for the Face with Carme Farré | "Come on. No, no, don't do that. Don't give me the pouty batface." We have video today (!) for our special guest Carme Farré, who founded FaceToned®, and she shares her experiences as part of an FSHD family and how her techniques for facial fitness can help the FSHD community. If interested, you can arrange a free consultation below:🔗 https://calendly.com/carmefarre/15min?month=2025-04and find more information:🌐 www.facetoned.com📚 courses.facetoned.com | — | ||||||
Showing 14 of 14
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
6 placements across 6 markets.
Chart Positions
6 placements across 6 markets.